4.6
CiteScore
2.2
Impact Factor
- ISSN 1674-8301
- CN 32-1810/R
4.6
2.2
| Citation: |
Juan Zhou, Yiran Xu, Luyao Wang, Yu Cong, Ke Huang, Xinxing Pan, Guangquan Liu, Wenqu Li, Chenchen Dai, Pengfei Xu, Xuemei Jia. LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47[J]. The Journal of Biomedical Research, 2024, 38(1): 51-65. DOI: 10.7555/JBR.37.20230097
|
Long noncoding RNA (lncRNA) IDH1 antisense RNA 1 (IDH1-AS1) is involved in the progression of multiple cancers, but its role in epithelial ovarian cancer (EOC) is unknown. Therefore, we investigated the expression levels of IDH1-AS1 in EOC cells and normal ovarian epithelial cells by quantitative real-time PCR (qPCR). We first evaluated the effects of IDH1-AS1 on the proliferation, migration, and invasion of EOC cells through cell counting kit-8, colony formation, EdU, transwell, wound-healing, and xenograft assays. We then explored the downstream targets of IDH1-AS1 and verified the results by a dual-luciferase reporter, qPCR, rescue experiments, and Western blotting. We found that the expression levels of IDH1-AS1 were lower in EOC cells than in normal ovarian epithelial cells. High IDH1-AS1 expression of EOC patients from the Gene Expression Profiling Interactive Analysis database indicated a favorable prognosis, because IDH1-AS1 inhibited cell proliferation and xenograft tumor growth of EOC. IDH1-AS1 sponged miR-518c-5p whose overexpression promoted EOC cell proliferation. The miR-518c-5p mimic also reversed the proliferation-inhibiting effect induced by IDH1-AS1 overexpression. Furthermore, we found that RNA binding motif protein 47 (RBM47) was the downstream target of miR-518c-5p, that upregulation of RBM47 inhibited EOC cell proliferation, and that RBM47 overexpressing plasmid counteracted the proliferation-promoting effect caused by the IDH1-AS1 knockdown. Taken together, IDH1-AS1 may suppress EOC cell proliferation and tumor growth via the miR-518c-5p/RBM47 axis.
We acknowledge and appreciate our institutional colleagues for their experimental technical support.
CLC number: R73-3, Document code: A
The authors reported no conflict of interests.
| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17–48. doi: 10.3322/caac.21763
|
| [2] |
Wang M, Zhang J, Wu Y. Tumor metabolism rewiring in epithelial ovarian cancer[J]. J Ovarian Res, 2023, 16(1): 108. doi: 10.1186/s13048-023-01196-0
|
| [3] |
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer[J]. BMJ, 2020, 371: m3773. doi: 10.1136/bmj.m3773
|
| [4] |
Salamini-Montemurri M, Lamas-Maceiras M, Lorenzo-Catoira L, et al. Identification of lncRNAs deregulated in epithelial ovarian cancer based on a gene expression profiling meta-analysis[J]. Int J Mol Sci, 2023, 24(13): 10798. doi: 10.3390/ijms241310798
|
| [5] |
Zhao S, Zhang X, Chen S, et al. Natural antisense transcripts in the biological hallmarks of cancer: powerful regulators hidden in the dark[J]. J Exp Clin Cancer Res, 2020, 39(1): 187. doi: 10.1186/s13046-020-01700-0
|
| [6] |
Xu F, Huang M, Chen Q, et al. LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1α pathway[J]. Cancer Res, 2021, 81(22): 5678–5691. doi: 10.1158/0008-5472.CAN-21-0281
|
| [7] |
Yang L, Chen Y, Liu N, et al. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN[J]. J Hematol Oncol, 2021, 14(1): 46. doi: 10.1186/s13045-021-01059-5
|
| [8] |
Liu Y, Zhang P, Wu Q, et al. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63[J]. Nat Commun, 2021, 12(1): 5232. doi: 10.1038/s41467-021-25552-0
|
| [9] |
Xiang S, Gu H, Jin L, et al. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect[J]. Proc Natl Acad Sci U S A, 2018, 115(7): E1465–E1474. doi: 10.1073/pnas.1711257115
|
| [10] |
Zhang N, Li Z, Bai F, et al. PAX5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy[J]. Cell Death Dis, 2019, 10(10): 734. doi: 10.1038/s41419-019-1932-3
|
| [11] |
Wang J, Quan Y, Lv J, et al. LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma[J]. Biochem Cell Biol, 2020, 98(5): 556–564. doi: 10.1139/bcb-2019-0465
|
| [12] |
Braga EA, Fridman MV, Moscovtsev AA, et al. LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms[J]. Int J Mol Sci, 2020, 21(22): 8855. doi: 10.3390/ijms21228855
|
| [13] |
Klar M, Hasenburg A, Hasanov M, et al. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO[J]. Eur J Cancer, 2016, 66: 114–124. doi: 10.1016/j.ejca.2016.07.014
|
| [14] |
Chang LC, Huang CF, Lai MS, et al. Prognostic factors in epithelial ovarian cancer: a population-based study[J]. PLoS One, 2018, 13(3): e0194993. doi: 10.1371/journal.pone.0194993
|
| [15] |
Rosendahl M, Høgdall CK, Mosgaard BJ. Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer[J]. Int J Gynecol Cancer, 2016, 26(4): 680–687. doi: 10.1097/IGC.0000000000000675
|
| [16] |
Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage[J]. J Natl Cancer Inst, 2019, 111(1): 60–68. doi: 10.1093/jnci/djy071
|
| [17] |
Martinez A, Pomel C, Filleron T, et al. Prognostic relevance of celiac lymph node involvement in ovarian cancer[J]. Int J Gynecol Cancer, 2014, 24(1): 48–53. doi: 10.1097/IGC.0000000000000041
|
| [18] |
Ataseven B, Grimm C, Harter P, et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 135(3): 435–440. doi: 10.1016/j.ygyno.2014.10.003
|
| [19] |
Wu S, Ding L, Xu H, et al. The long non-coding RNA IDH1-AS1 promotes prostate cancer progression by enhancing IDH1 enzyme activity[J]. Onco Targets Ther, 2020, 13: 7897–7906. doi: 10.2147/OTT.S251915
|
| [20] |
Chen L. Linking long noncoding RNA localization and function[J]. Trends Biochem Sci, 2016, 41(9): 761–772. doi: 10.1016/j.tibs.2016.07.003
|
| [21] |
Fernandes JCR, Acuña SM, Aoki JI, et al. Long non-coding RNAs in the regulation of gene expression: physiology and disease[J]. Non-Coding RNA, 2019, 5(1): 17. doi: 10.3390/ncrna5010017
|
| [22] |
Fan Y, Wang L, Han X, et al. LncRNA ASB16-AS1 accelerates cellular process and chemoresistance of ovarian cancer cells by regulating GOLM1 expression via targeting miR-3918[J]. Biochem Biophys Res Commun, 2023, 675: 1–9. doi: 10.1016/j.bbrc.2023.06.068
|
| [23] |
Su M, Huang P, Li Q. Long noncoding RNA SNHG6 promotes the malignant phenotypes of ovarian cancer cells via miR-543/YAP1 pathway[J]. Heliyon, 2023, 9(5): e16291. doi: 10.1016/j.heliyon.2023.e16291
|
| [24] |
Li Y, Zhu X, Zhang C, et al. Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR[J]. Histol Histopathol, 2023, 9: 18620. doi: 10.14670/HH-18-620
|
| [25] |
Flor I, Bullerdiek J. The dark side of a success story: microRNAs of the C19MC cluster in human tumours[J]. J Pathol, 2012, 227(3): 270–274. doi: 10.1002/path.4014
|
| [26] |
Dyrskjøt L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro[J]. Cancer Res, 2009, 69(11): 4851–4860. doi: 10.1158/0008-5472.CAN-08-4043
|
| [27] |
Zhao J, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis[J]. Childs Nerv Syst, 2009, 25(1): 13–20. doi: 10.1007/s00381-008-0701-x
|
| [28] |
Kinouchi M, Uchida D, Kuribayashi N, et al. Involvement of miR-518c-5p to growth and metastasis in oral cancer[J]. PLoS One, 2014, 9(12): e115936. doi: 10.1371/journal.pone.0115936
|
| [29] |
He J, Han Z, Luo J, et al. Hsa_Circ_0007843 acts as a miR-518c-5p sponge to regulate the migration and invasion of colon cancer SW480 cells[J]. Front Genet, 2020, 11: 9. doi: 10.3389/fgene.2020.00009
|
| [30] |
Fossat N, Radziewic T, Jones V, et al. Conditional restoration and inactivation of Rbm47 reveal its tissue-context requirement for viability and growth[J]. Genesis, 2016, 54(3): 115–122. doi: 10.1002/dvg.22920
|
| [31] |
Radine C, Peters D, Reese A, et al. The RNA-binding protein RBM47 is a novel regulator of cell fate decisions by transcriptionally controlling the p53-p21-axis[J]. Cell Death Differ, 2020, 27(4): 1274–1285. doi: 10.1038/s41418-019-0414-6
|
| [32] |
Sakurai T, Isogaya K, Sakai S, et al. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma[J]. Oncogene, 2016, 35(38): 5000–5009. doi: 10.1038/onc.2016.35
|
| [33] |
Guo T, You K, Chen X, et al. RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator[J]. Cell Death Discov, 2022, 8(1): 320. doi: 10.1038/s41420-022-01112-3
|
| [34] |
Qin Y, Sun W, Wang Z, et al. RBM47/SNHG5/FOXO3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma[J]. Cell Death Dis, 2022, 13(3): 270. doi: 10.1038/s41419-022-04728-6
|
| [35] |
Shen D, Jiang Y, Li J, et al. The RNA-binding protein RBM47 inhibits non-small cell lung carcinoma metastasis through modulation of AXIN1 mRNA stability and Wnt/β-catentin signaling[J]. Surg Oncol, 2020, 34: 31–39. doi: 10.1016/j.suronc.2020.02.011
|
| [1] | Izzatullo Ziyoyiddin o`g`li Abdullaev, Ulugbek Gapparjanovich Gayibov, Sirojiddin Zoirovich Omonturdiev, Sobirova Fotima Azamjonovna, Sabina Narimanovna Gayibova, Takhir Fatikhovich Aripov. Molecular pathways in cardiovascular disease under hypoxia: Mechanisms, biomarkers, and therapeutic targets[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240387 |
| [2] | Chen Li, Kerui Wang, Xingfeng Mao, Xiuxiu Liu, Yingmei Lu. Upregulated inwardly rectifying K+ current-mediated hypoactivity of parvalbumin interneuron underlies autism-like deficits in Bod1-deficient mice[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240394 |
| [3] | Siyun Zhou, Yan Li, Wenqing Sun, Dongyu Ma, Yi Liu, Demin Cheng, Guanru Li, Chunhui Ni. circPVT1 promotes silica-induced epithelial-mesenchymal transition by modulating the miR-497-5p/TCF3 axis[J]. The Journal of Biomedical Research, 2024, 38(2): 163-174. DOI: 10.7555/JBR.37.20220249 |
| [4] | Dandan Zheng, Xiya Zhang, Jia Xu, Shuwen Chen, Bin Wang, Xiaoqin Yuan. LncRNA LINC01503 promotes angiogenesis in colorectal cancer by regulating VEGFA expression via miR-342-3p and HSP60 binding[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240190 |
| [5] | Pei Tan, Mu Xu, Junjie Nie, Jian Qin, Xiangxiang Liu, Huiling Sun, Shukui Wang, Yuqin Pan. LncRNA SNHG16 promotes colorectal cancer proliferation by regulating ABCB1 expression through sponging miR-214-3p[J]. The Journal of Biomedical Research, 2022, 36(4): 231-241. DOI: 10.7555/JBR.36.20220049 |
| [6] | Zhu Ping, Shan Xia, Liu Jinhui, Zhou Xin, Zhang Huo, Wang Tongshan, Wu Jianqing, Zhu Wei, Liu Ping. miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5[J]. The Journal of Biomedical Research, 2019, 33(6): 382-390. DOI: 10.7555/JBR.33.20180078 |
| [7] | Wang Jing, He Xuezhi, Lu Xiyi, Amin Karim Muhammad, Miao Dengshun, Zhang Erbao. A novel long non-coding RNA NFIA-AS1 is down-regulated in gastric cancer and inhibits proliferation of gastric cancer cells[J]. The Journal of Biomedical Research, 2019, 33(6): 371-381. DOI: 10.7555/JBR.33.20190015 |
| [8] | Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065 |
| [9] | Yi Zhang, Jing Wu, Junya Liang, Xing Huang, Lei Xia, Dawei Ma, Xinyu Xu, Pingping Wu. Association of serum lipids and severity of epithelial ovarian cancer: an observational cohort study of 349 Chinese patients[J]. The Journal of Biomedical Research, 2018, 32(5): 336-342. DOI: 10.7555/JBR.32.20170096 |
| [10] | Lihong Chen, Lianxiang Li, Feng Chen, Dalin He. Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma[J]. The Journal of Biomedical Research, 2012, 26(4): 274-277. DOI: 10.7555/JBR.26.20110103 |
| 1. | Wang X, Zhou Y, Wang L, et al. Fascin-1 Promotes Cell Metastasis through Epithelial-Mesenchymal Transition in Canine Mammary Tumor Cell Lines. Vet Sci, 2024, 11(6): 238. DOI:10.3390/vetsci11060238 |
| 1. | Wang X, Zhou Y, Wang L, et al. Fascin-1 Promotes Cell Metastasis through Epithelial-Mesenchymal Transition in Canine Mammary Tumor Cell Lines. Vet Sci, 2024, 11(6): 238. DOI:10.3390/vetsci11060238 |
Figures(6) / Tables(4)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
Authors and Reviewers
DownLoad: